Proactive investorsLogo Proactive Investors UK Website

Search field
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: ASX:AVH
News: Latest news
Web Site: Avita Medical
Other Articles: 17-08-2009

RSS - Subscribe to the News Today on Proactive UK ▼

Monday February 08, 08:40Alliance Pharma gains 18 new prescription products in acquisition

The company is paying up to £17.8m for privately owned Cambridge Laboratories and expects the deal to be significantly earnings enhancing in the current full year.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Monday February 08, 09:33Tethys Petroleum achieves flow rates of over 5,400 bopd at AKD01 discovery in Kazakhstan

Current mapping indicates that the AKD01 well is in a downdip location on the prospect Doris with approximately 56 metres of elevation updip of the well, potentially bringing the entire lower reservoir into the oil zone.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Tuesday February 09, 01:53Chindex International reports increasing medical and healthcare revenues

Healthcare products and services group Chindex International (NASDAQ: CHDX) reported increasing revenues as it continued to expand its operations in the People’s Republic of China (PRC).

FULL ARTICLE ►
Avita Medical

Avita Medical

Avita Medical Limited (ASX: AVH) is a publicly listed, global medical technology company trading on the Australian Stock Exchange. The company develops and distributes highly innovative products in Regenerative and Respiratory Medicine.

The company's regenerative and tissue-engineered products provide revolutionary solutions utilising the patient's own skin and the regenerative capability of the human body to treat a wide range of wounds, scars and skin defects.

ReCell® is a stand-alone, rapid cell harvesting device that enables surgeons to treat skin defects using the patient's own cells.

Monday, August 17, 2009

Avita Medical secures key regulatory approval for ReCell® spray on skin for Chinese market

company news image

In a move that has spurred the Avita Medical (ASX: AVH) share price today, up 78% to 20.5 cents, Avita has secured regulatory approval for its ReCell® Autologous Spray-On Skin from the Chinese State Food and Drug Administration (SFDA).

The SFDA is responsible for regulation and supervision of medical products and is the competent authority for drug regulation in mainland China.

ReCell has been issued an unrestricted import license. Avita is targeting the burgeoning Chinese middle class for its ReCell product.

CEO of Avita Medical, Dr William Dolphin, said, “China is a key market for the company’s products. ReCell addresses the growing demand for cosmetic surgery, scar revision and burns treatment. The product is being targeted to China’s burgeoning middle class, a rapidly growing segment of the country’s 1.3 billion people.”

The target market for ReCell includes plastic and reconstructive surgeons, dermatologists, burns specialists and cosmetic specialists at high end military hospitals as well as larger private hospitals in major metropolitan centres of China.

The ReCell technology has strong sales potential in China where the cosmetics and plastics markets are growing exponentially. Estimates of the annual market are approximately US$2.4 billion. There are more than 100,000 cosmetic surgery clinics in China’s major hospitals.

ASX-listed Helicon Group (ASX:HCG) will be distributing ReCell through its established inmarket, specialist partners that it uses to distribute a range of medical devices.

AddThis Feed Button
Register here to be notified of future Avita Medical articles.

Other Avita Medical news

More news ►

Investors interested in Avita Medical recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.